Press Releases.

Search

Year

May 04, 2023

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , May 04, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc.

April 28, 2023

PDF Version

Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4,

March 29, 2023

PDF Version

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

SOUTH SAN FRANCISCO, Calif. , March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker , Founder and Chief Scientific Officer, and Dr. James F. Cummings , Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in

March 17, 2023

PDF Version

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 17, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast on the health

March 15, 2023

PDF Version

Vaxart Provides Business Update and Full Year 2022 Financial Results

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance cross-reactivity and potency with the goal of developing a pan-betacoronavirus vaccine Portfolio

March 08, 2023

PDF Version

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March

February 14, 2023

PDF Version

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus